Division of GlaxoSmithKline PLC
Latest From Domantis Ltd.
Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.
Biochemist Greg Winter has scientifically contributed to some of the pharmaceutical industry's biggest commercial and therapeutic success stories. He tells Scrip how he feels about being labelled a pioneer and why he is still wary of the boardroom.
David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.
Though it has left behind the “industrialized” R&D approaches from the 1990s, Glaxo thinks its R&D revolution has produced strong growth that will get it back into major markets and maintain an output of three to five significant drug approvals per year. With that progress in sight, the firm is ready to transform its manufacturing and commercial model in the same way it recreated R&D.
- Therapeutic Areas
- Respiratory, Pulmonary
- Diversys Ltd.
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Robert T Connelly, CEO
Ian Tomlinson, PhD, EVP & CSO
Pamela Hay, Chief Commercial Officer
- Contact Info
Phone: (44) 1223 226 900
315 Cambridge Science Park
Cambridge, CB4 OWG
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.